China’s Helicobacter Pylori Vaccine Completes Phase III Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
According to China's Ministry of Science and Technology, the Third Military Medical University of the PLA has successfully developed an oral recombinant Helicobacter pylori vaccine. The world's first such vaccine, the product has completed Phase III clinical trials and obtained the country's new drug certification. Trial results showed the vaccine to be effective and safe, with a protection rate of 72 percent in preventing H. pylori infection. The bacteria, which afflict some 50 percent of people in developing countries, cause gastric ulcers and show close correlation with stomach cancer. The developer of the vaccine, along with investors, are working hard to bring it to market as soon as possible. (Click here for more - Chinese Language)